Targeted Survivin DC Cell Injection for the Treatment of GBM
Clinical trial NCT06524063 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT06524063
- Sponsor
- Beijing Tricision Biotherapeutics Inc
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-01
- Primary completion
- 2025-12-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.